{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Devin J"],"funding":["INCA","European Research Council","ANR","French National Research Agency"],"pagination":["998-1012"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9359736"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["82(6)"],"pubmed_abstract":["Diffuse large B-cell lymphoma (DLBCL) is the most common hematological malignancy. Although more than half of patients with DLBCL achieve long-term remission, the majority of remaining patients succumb to the disease. As abnormal iron homeostasis is implicated in carcinogenesis and the progression of many tumors, we searched for alterations in iron metabolism in DLBCL that could be exploited to develop novel therapeutic strategies. Analysis of the iron metabolism gene expression profile of large cohorts of patients with DLBCL established the iron score (IS), a gene expression-based risk score enabling identification of patients with DLBCL with a poor outcome who might benefit from a suitable targeted therapy. In a panel of 16 DLBCL cell lines, ironomycin, a promising lysosomal iron-targeti"],"journal":["Cancer research"],"pubmed_title":["Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma."],"pmcid":["PMC9359736"],"funding_grant_id":["647973","PLBIO19","PLBIO18-362 PIT-MM","ANR-18-CE15-0010-01","2017-CE15-0024-01","ANR-10-INBS-04"],"pubmed_authors":["Abouladze M","Lin YL","Garcia De Paco E","Pasero P","Karmous Gadacha O","Caneque T","Mondoulet L","Devin J","Cartron G","Bret C","Moreaux J","Veyrune JL","Rodriguez R"],"additional_accession":[]},"is_claimable":false,"name":"Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma.","description":"Diffuse large B-cell lymphoma (DLBCL) is the most common hematological malignancy. Although more than half of patients with DLBCL achieve long-term remission, the majority of remaining patients succumb to the disease. As abnormal iron homeostasis is implicated in carcinogenesis and the progression of many tumors, we searched for alterations in iron metabolism in DLBCL that could be exploited to develop novel therapeutic strategies. Analysis of the iron metabolism gene expression profile of large cohorts of patients with DLBCL established the iron score (IS), a gene expression-based risk score enabling identification of patients with DLBCL with a poor outcome who might benefit from a suitable targeted therapy. In a panel of 16 DLBCL cell lines, ironomycin, a promising lysosomal iron-targeti","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-04T21:05:01.635Z","creation":"2025-04-04T21:05:01.635Z"},"accession":"S-EPMC9359736","cross_references":{"pubmed":["35078814"],"doi":["10.1158/0008-5472.CAN-21-0218"]}}